X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/06/09/2685438/0/en/Finch-Announces-Reverse-Stock-Split-of-Common-Stock.html
https://www.globenewswire.com/news-release/2023/05/10/2665380/0/en/Finch-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
https://www.fiercebiotech.com/biotech/finch-pinches-pennies-stretching-cash-2025-after-layoffs-and-trial-discontinuation
https://www.globenewswire.com/news-release/2023/03/23/2633655/0/en/Finch-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Updates.html
https://www.fiercebiotech.com/biotech/frosty-funding-forecast-forces-finch-stop-phase-3-trial-lay-95-staff-and-seek-buyers-assets
https://www.globenewswire.com/news-release/2022/11/10/2552963/0/en/Finch-Therapeutics-Provides-Corporate-Updates-and-Reports-Third-Quarter-2022-Financial-Results.html
https://www.globenewswire.com/news-release/2022/11/09/2551976/0/en/Finch-Therapeutics-to-Present-at-the-Jefferies-London-Healthcare-Conference-and-Evercore-ISI-HealthCONx-Conference.html
https://www.globenewswire.com/news-release/2022/10/24/2539916/0/en/Finch-Therapeutics-Presents-PRISM-EXT-Biomarker-Data-at-ACG-2022-and-Proceeds-with-Patient-Dosing-in-Phase-3-Trial-of-CP101-in-Recurrent-C-Difficile-Infection.html
https://www.fiercebiotech.com/biotech/finch-axes-more-third-staff-days-after-takeda-clips-its-fiscal-wings
https://www.biospace.com/article/finch-therapeutics-regains-rights-to-two-ibd-drugs-licensed-to-takeda-/
Market Place
Share 
